New Jersey: Camden Will Consider Medical Marijuana Centers at Land-Use Hearing

2/6/2012 – A zoning hearing will be held before the Land-Use Board of Camden New Jersey on Monday February 6, 2012. These are normally rather dull meetings but on the agenda this week is a variance to allow one of the six state-approved medical marijuana Alternative Treatment Centers (ATCs). Several municipalities around the state have already turned down the facilities. This has left the Garden State medical cannabis law completely stalled as none of the ATCs can find a home.

But in Camden there are some new factors to the attempt that could yield a different outcome. Instead of one of the multi-million dollar ATCs seeking permission this time it is an individual going before the local zoning board.  Frank Fulbrook has owned property in Camden since the 1960’s. He is also a local activist and a meticulous scholar. This writer interviewed Fulbrook in 2007 after he mapped all of the open-air drug markets in Camden – a rather large and risky task.

Fulbrook is considered an expert in the local planning code; he actually sat on Camden’s Land-Use Board for many years. Now Fulbrook has partnered up with a friend who owns a warehouse, they will seek the zoning approval on their own and then lease the space to one of the ATCs. Rather than coming in from outside the community asking to open such an innovative business Fulbrook and his partner are super-locals, which should give them a much better shot.

Even with all of these ducks in a row there are other factors. If you have never been to New Jersey you have still probably heard of Camden. The city sits across the Delaware River from Philadelphia and remains a sore spot in the state. Yes there are happy seals barking from the gleaming NJ Aquarium, a bustling Rutgers Campus and some strips of success. But recent budget cuts have escalated the violence and blight across 95% of the already impoverished community.

Governor Chris Christie and the NJ Department of Health and Senior Services (DHSS) have severely altered the plans for the cannabis program. Among the buffet of new restrictions was the elimination of the provisions that allowed for the home delivery of  NJ’s medicinal cannabis. This means that patients or their designated caregiver must visit the ATCs in person. Although Camden is centrally located and has ample connections to public transportation, seriously ill NJ residents may not want to venture into the dangerous city for their legal marijuana.

Another interesting note is that half of the Camden police force was recently laid off. This has led to a sharp increase in the presence of federal agents – mainly in the Drug Enforcement Administration or DEA. If the ATC is approved in Camden there may be some friction between a warehouse growing marijuana for half of South Jersey’s patients and the DEA.

Still Fulbrook is hopeful for success, “This is a good place for one of these Alternative Treatment Centers. It’s the largest population concentration in South Jersey and all roads lead to Camden. It’s hub of highways and mass transit. But there are people right in Camden that have serious medical problems like HIV/AIDS …there are a lot of people right here who can benefit from marijuana as medicine. And this can create jobs.”

The Coalition for Medical Marijuana New Jersey (CMMNJ) is planning to have advocates at the hearing to testify.

Chris Goldstein is a respected marijuana reform advocate. As a writer and radio broadcaster he has been covering cannabis news for over a decade. Questions?  [email protected]

New Jersey Attorney General Meets With Medical Marijuana Advocates

NJ State House by Freitag

New Jersey State House by C. David Freitag

Editor Chris Goldstein was quoted in this press release today –

FOR IMMEDIATE RELEASE 5/25/2011
The Coalition for Medical Marijuana New Jersey (CMMNJ)
www.cmmnj.org

New Jersey Attorney General Meets With Medical Marijuana Advocates

Trenton – New Jersey Attorney General Paula Dow sat down with the Coalition for Medical Marijuana NJ (CMMNJ) on May 24th at her office in Trenton.  The AG and her staff held the meeting to hear concerns from local advocates about the compassionate use marijuana program that has now been suspended by Governor Christie.

Ken Wolski RN, the executive director of CMMNJ, was grateful for the interaction.

“Attorney General Paula Dow and First Assistant Phillip Kwon took time out their demanding schedules to listen to some very serious issues for New Jersey’s medical marijuana law,” said Wolski, “Qualifying patients continue to wait for this program and we hope that some of their concerns were heard. The Office of the Attorney General plays a key role in the implementation and administration of the compassionate use law.”

On April 22, 2011 Dow sent a letter to the Department of Justice in Washington DC requesting clarification about the medical marijuana law. Several US Attorneys have recently issued letters in other states with a clear description of how federal authorities will prosecute medical marijuana facilities, even if they are permitted under state law. In Washington, Montana and other states the letters were accompanied by DEA raids of local medical cannabis dispensaries.

NJ Attorney General Paula Dow stated in the meeting that she sent a follow-up letter to the US Department of Justice, addressed to US Attorney General Eric Holder, on May 23, 2011.

Paul Fishman, the US Attorney for New Jersey, has not sent any communication regarding the NJ medical marijuana law before or after Dow’s requests. A spokesperson at the US DOJ said the April 22nd letter from New Jersey had been received and was under review.

Chris Goldstein, the media coordinator at CMMNJ also attended the meeting.

“Not a single person in New Jersey has been able to register for medical cannabis, despite many promises from Governor Christie,” said Goldstein, “But I think that we had a meaningful exchange of new ideas with Attorney General Dow. The intent of The Compassionate Use Medical Marijuana Act is to grant legal access to seriously ill residents. There are some methods that the AG’s office can explore to actively protect New Jersey’s medical cannabis patients today.”

New Jersey passed the first compassionate use law in the country that forces patients into a centralized system of just six Alternative Treatment Centers to access all of their state-legal cannabis. There are no provisions in the NJ law to allow patients or caregivers to cultivate cannabis on their own. The law was supposed to have been fully implemented in the summer of 2010 but has suffered numerous delays.

CMMNJ’s Ken Wolski is looking forward to meeting with the one state official who has exercised the most influence over the medical marijuana law: Governor Chris Christie.

“It is long past time for Governor Christie to actually meet with patients and advocates in our state to discuss the compassionate use law.”

New Jersey: 109 Doctors Register for Medical Marijuana

1/11/2012 – A spokesperson at the New Jersey Department of Health and Senior Services (DHSS), Donna Leusner, said that there are one hundred and nine physicians registered with the state’s medicinal marijuana program.  This is an increase of just nineteen since the last check on the list in June 2011.

The Garden State is requiring the nation’s first registry for doctors who wish to recommend cannabis therapy. The separate registry for seriously ill patients is not open yet. Qualifying NJ patients do not have any protection from arrest or prosecution if they are caught with marijuana.

The finalized regulations for the “Medicinal Marijuana Program” were released by NJDHSS in December 2011. The doctor registry was not written into the law, but it is part of these new regulations. Patients, scientists, doctors, nurses and medical professionals testified several times before Legislative and DHSS hearings that the registry was unnecessary and contained requirements that would discourage participation.

Ken Wolski, a registered nurse and Executive Director of The Coalition  for Medical Marijuana New Jersey (CMMNJ) wrote about the chilling effect of the registry.

” The physician registration program is even more limiting. A new requirement says that physicians must certify that they have completed medical education in Addiction Medicine and Pain Management within the past two years. Physicians must include the course title that covers these two areas, or they will be rejected from the registry.

This is a curious add-on. Marijuana is approximately as addictive as caffeine. Physicians should not be required to take a course in addiction medicine for recommending a substance with documented low addiction potential.” read full

The former DHSS Commissioner Dr. Poonam Alaigh testified before the NJ Senate Health Committee in March 2011 that no similar requirements existed for doctors dispensing other drugs, even narcotics like morphine.

There are more than 28,000 physicians in New Jersey. The low number of registered doctors participating in the cannabis registry so far is seen as a problem by advocates and patients. The NJ Board of Medical Examiners, The NJ Department of Consumer Affairs and DHSS are tasked with providing information to doctors about the cannabis program.

The physician registry for medical cannabis began in October 2010. The list of the registered doctors is currently not public, leaving many patients wondering how they will access the program when or if it becomes operational. DHSS spokesperson Donna Leusner said that the possibility of publishing the doctor list is “under review.”

Two years after the Compassionate Use Medical Marijuana Act was signed into law, the controversial physician registry is the only part of the NJ program that appears to be online.

None of the six Alternative Treatment Centers (ATCs) that will grow and dispense the cannabis have received their final permits from the state. Several have recently failed in their bids for municipal land-use variances. This means that there is no legal marijuana available in New Jersey.

The severely restrictive regulations have put qualifying residents in a Catch-22: Until one of the ATCs actually opens their doors the specially qualified doctors will not be able to register patients with the state.

Chris Goldstein is a respected marijuana reform advocate. As a writer and radio broadcaster he has been covering cannabis news for over a decade. Questions?  [email protected]

New Human Research on CBD, Endocannabinoids and Depression

ICRS logo

8/8/2011 – The International Cannabinoid Research Society (ICRS) meeting  in Chicago last month showcased new data on cannabinoids gathered from human subjects. Most bio-medical science happens on rats or in petri dishes, so any studies on people are always notable. The ICRS is a unique and concentrated pool of cannabinoid scientists presenting the latest breakthroughs at our annual meetings.

The second day of the 2011 ICRS meeting had a Psychiatric Session that included these interesting topics:

Danieal Hauer, Ludwig-Maimilians University (Germany) discussed results from human subject who had undergone cardiac surgery.  23.5% percent of patients were thought to have diagnosable symptoms of depression after 6 months post-surgery.  This population of depressed patients had lower blood levels of Anandamide, an endocannabinoid. The doctors suggest that patients with lower endocannabinoid levels during the peri-opertaive stage are at a higher risk of developing depression.

Mateus Bergamaschi, University Sao Paulo Brazil, showed results from a human study on the effects of pure CBD to treat people with social phobia.  Participants were all healthy college undergraduates. They divided into different groups and were given 2 minutes to prepare a 4 minute oral presentation on “the public transportation system of your city.” The participants who received an oral of CBD had lower anxiety scores than the placebo group. The researchers conclude that this is another study which demonstrates the anti-anxiety effects of CBD and additional double blind, placebo controlled studies are needed.

Andrea Dlugos (University of Muenster, University of Chicago) presented the first data on human subjects which indicates that stress can increase the levels of many endocannabinoids. Acute stress increases N-Acylethanolamines, i.e., AEA, in healthy humans. Basla serum levels of AG and AEA were found to be lower in depressed women. Functional FAAH gene variants influence response to acute stress. eCB increases are correlated to circulating levels of stress indicators.  Stress increases AEA, PEA, OEA but not 2AG, 2OG. Psychosocial specific stress increases some levels. Interestingly, Caucasians show an increase in certain cannabinoids that was not seen in African Americans and Asians.  The authors note that cortisol and PEA share a common mechanism that warrants further study.

These three sets of research could have beneficial applications if they are developed. Testing the endocannabinoid levels to help identify those at risk for depression after heart surgery would be a simple way of averting this negative outcome. It is also exciting to see pure CBD used in a psychological experiment with humans demonstrating a promising treatment from an easily acquired extract.

The ICRS meeting was jam packed with amazing new science. We’ll have more from the presentations in future posts.

Jahan Marcu is currently investigating the pharmacology of cannabinoid receptors. He was working at the California Pacific Medical Center Research Institute when exciting discoveries were made showing enhanced anti-cancer effects with THC and CBD from the Cannabis plant. The findings were published in the Journal of Molecular Cancer Therapeutics. In 2009 he received the Billy Martin Award from the International Cannabinoid Research Society (ICRS). Jahan is currently the vice-chair the Medical and Scientific Advisory Board at Americans for Safe Access (ASA). Questions?   Contact    [email protected]

DISCLAIMER: The views and opinions expressed are those of the author and do not necessarily represent any University, business or affiliates. While the information provided in this blog is from published scientific studies it is not intended to diagnose or treat any disease.

New Hampshire Tables Medical Marijuana Bill

NH Legislators consider HB 442 in April

5/11/2011 UPDATE The New Hampshire Senate has postponed legislative action on the medical marijuana bill, HB 442. The move today means that the bill may not get a floor vote in the Senate, even though the House passed the measure 221-94 in March.

The sticking point seems to be the years-long fight between Governor John Lynch and the NH Legislature over this issue. Lynch vetoed a medical marijuana bill in 2009 and promised to do the same this year if the bill passed again.

Activists who were in attendance at the New Hampshire legislative session today were disappointed that the Senate didn’t stand up to Lynch. An attempt to overturn the medical marijuana veto in 2009  fell heartbreakingly short by just two votes. Patient advocates on the ground felt that the Legislature should hold firm in the face of Lynch’s threat and try again to force the bill through.

Kirk McNeill at NH Compassion pulled no punches in his reaction to the Senate’s vote, “Today the NH Senate participated in an act of legislative cowardice by tabling HB442.”

But postponing the legislation did not quite kill it. A spokesperson at NH Senator Ray White’s office told Freedomisgreen.com that technically HB 442 could be brought for a floor vote again before the legislative session ends in June. However, the prospects for the bill actually making it to the Senate this year remain unclear.

NH Compassion’s McNeill said, “Patients deserve to have their treatment options be a decision between them and their doctors, a decision based on science.  Laws against the medicinal use of cannabis are quiet simply, interference in the doctor patient relationship backed up by men with guns.”

More info at http://nhcompassion.org/

Questions?  [email protected]

Chris Goldstein is a respected marijuana reform advocate. As a writer and radio broadcaster he has been covering cannabis news for over a decade. He volunteers with local groups to change prohibition laws including PhillyNORML and The Coalition for Medical Marijuana New Jersey.

New Hampshire Medical Marijuana Hearing This Week

New Hampshire MS Patient Ellen McClung

On April 14th New Hampshire’s medical marijuana bill, HB 442, will have a hearing in the Senate at 1:00 pm. The legislation has already been approved by the House Health, Human Services, and Elderly Affairs Committee and passed a vote by the full House (221-96) on March 16th.

Kirk McNeil, the volunteer Executive Director of New Hampshire Compassion (which is a special project under New Hampshire Coalition for Common Sense Marijuana Policy) and had this to say about the upcoming hearing:

“I’m very excited about the senate hearing coming up in just a few days. We have a lot of senate support. One of the concerns that a lot of legislators have previously expressed was that it might have been a backdoor legalization bill, but it’s not. It is very much a medical marijuana bill. The bill focuses on the sickest patients and provides some controls to enable them to not worry.”

To donate to New Hampshire Compassion and the on-going work of its hardworking volunteers, please visit them here.

New Hampshire: Medical marijuana bill passes key vote

photo by C. David Freitag

Remember that School House Rock segment on how a bill becomes a law? Just put that on repeat. A House committee in New Hampshire approved legislation this week to legalize medical marijuana. This is an important step as bills often need to be heard by several committees before they can pass all-important floor votes.

But New Hampshire had a similar bill run this gauntlet just two years ago. Medical marijuana legislation passed in 2009 only to be vetoed by Governor John Lynch.

The resulting attempt by the General Court to overturn the veto missed by just two votes in the state Senate.

Advocates on the ground were buoyed by the 14-3 vote on the House Health, Human Services and Elderly Affairs Committee who recommended that House Bill 442 be passed on the floor.

Polling shows that public support for medical marijuana in New Hampshire runs above 70%.

New England voters are demonstrating a visible groundswell of support for changing local cannabis laws.  Connecticut: Public backs marijuana reforms

Grassroots information: http://nhcommonsense.org/

New Dr. Oz Video with NJ Medical Marijuana Patient

On March 29th The Dr. Oz Show aired a full-length program discussing medical marijuana that included Montel Williams. But one of the segments that ended up on the cutting room floor featured Sandy Faiola of Asbury Park, New Jersey. Like Montel, Sandy lives with Multiple Sclerosis and uses cannabis to treat her condition. Because the compassionate use law is not yet working in the Garden State she must continue to risk arrest to access her medication. She has testified on many occasions before the state Legislature in Trenton and has appeared in demonstrations for other MS patients. Yesterday Dr. Oz posted the two-part video with Sandy online.

Links are below:

NBA star hopes for medical marijuana business in RI

The Providence Journal reported today that Cuttino Mobley, a Philadelphia native who has played for the Houston Rockets and New York Knicks, is hoping to open a medical marijuana dispensary in Rhode Island.

“You get it after a while,” Mobley said. “You know what you’re supposed to do.”

One of the things he wants to do now is start a wellness center in Warwick, one that will be allowed to dispense medical marijuana. He says he got interested in the field of wellness both through his own medical condition and those of other people close to him, and adds that the health field is one of the fastest growing in the country. Read full article at projo.com

Rhode Island is looking to license medical marijuana supply facilities.

Right now qualified patients or their caregivers must cultivate the cannabis on their own. Rhode Island does allow of collective gardens to be formed to help assure safe access.

Entrepreneurs, green with envy over the West Coast, are casting an emerald gaze at the domestic cannabis industry opening up back East.

Last year fifteen groups endured an intense application process in Rhode Island only to have them all be denied by the state.

This week, after a second round of applications, RI  again delayed the announcement if anyone will get a dispensary permit this year.

Cuttino Mobley was forced to leave his promising career in the NBA after doctors discovered that he has an enlarged heart.

The interview in The Providence Journal hints that Mobley is taking the right attitude into a business that needs to serve sick and dying residents.

It is refreshing to see a sports celebrity’s business venture be something more altruistic than a clothing line or body spray!

More information: http://ripatients.org

Chris Goldstein is a respected marijuana reform advocate. As a writer and radio broadcaster he has been covering cannabis news for over a decade.  He volunteers with local groups to change prohibition laws including PhillyNORML and The Coalition for Medical Marijuana New Jersey. He enjoys old school hip-hop, vintage airplanes and changing the world. Contact chris { at } freedomisgreen.com

Natural and Synthetic Cannabinoids Treat Glaucoma

Glaucoma – WikiMedia Commons image

A recent review on the applications of cannabinoids for the treatment of Glaucoma suggests that some of these compounds may be “ideal drugs” to manage this disease. The authors call for additional studies that could examine the safety and effectiveness in order to integrate these cannabinoid compounds into daily, clinical use.

Abstract:  Cannabinoid applications in glaucoma.

[Article in English, Spanish]

Departamento de Biología Celular e Histología, Grupo de Oftalmo-Biología Experimental (GOBE), Facultad de Medicina, Universidad del País Vasco (UPV/EHU), Leioa, Vizcaya, España.

Introduction

Glaucoma is a slowly progressive optic neuropathy that is one of the leading causes of legal blindness throughout the world. Currently there is a limited group of topical drugs for the medical treatment of glaucoma is currently limited, and research needs to be focused on new therapeutic horizons, such as the potential usefulness of the cannabinoid agonists for the treatment of glaucoma.

Aim

To review the current scientific literature related to the beneficial effects derived from the different ways of administration of cannabinoids indicated for the glaucomatous optic neuropathy.

Development

Cannabinoid receptors have shown an intense expression in ocular tissues implicated in the regulation of the intraocular pressure, as well as inner layers of the retina. Through activation of CB1 and CB1 specific receptors and through other still unknown pathways, the cannabinoid agonists have shown both a clear hypotensive, as well as an experimentally proved neuroprotective effect on retinal ganglion cells.

Conclusions

Some cannabinoid agonists (WIN 55212-2, anandamide) have demonstrated, in experimental studies, to act as «ideal drugs» in the management of glaucoma, as they have been shown to have good tolerability after topical application, efficiently reduce intraocular pressure, and behave as neuroprotectors on retinal ganglion cells.

Further studies as regards the safety and clinical assays must be carried out in order to examine the effectiveness of these drugs for the treatment of glaucoma in our daily clinical practice.

Read more